Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Aducanumab Approved For All Alzheimer’s Patients

6/7/2021

 
The FDA approved aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s Disease. Use of aducanumab was not limited to patients with early Alzheimer’s, similar to the patient populations in the ENGAGE and EVOLVE trials. Rather it was approved for use in any patient with Alzheimer’s disease.
 
The prescribing information for aducanumab contains a warning for amyloid-related imaging abnormalities (ARIA). ARIA usually presents as transient, symptomatic swelling in the brain. But some patients may develop headache, confusion, dizziness, vision changes, or nausea with ARIA. In addition to ARIA, the most common adverse effects include headache, fall, diarrhea, and confusion/delirium/altered mental status/disorientation.  
 
A review by the FDA’s Division of Neurology concluded that positive data from Emerge and a Phase II trial provided substantial evidence of effectiveness to support approval of aducanumab. However, a review by the FDA’s Office of Biostatistics concluded that a new trial was needed, because of the conflicting evidence seen in EMERGE and ENGAGE. 
 
The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted 0 yes, 10 no and 1 uncertain on whether there was enough evidence to recommend approval of aducanumab for the treatment of Alzheimer’s disease in November 2020. The FDA extended the review date for aducanumab by three months (March to June) to allow additional time to review new data Biogen had submitted to satisfy an FDA information request.
 
As part of the approval, the FDA is requiring Biogen, to conduct a new clinical trial to verify the aducanumab’s clinical benefit.
 
Biogen set the annual price for aducanumab at $56,000 a year, which is much higher than ICER’s cost effectiveness estimates of $2,500 to $8,300. ICER estimated that even in the most optimistic case, where only data from the positive EMERGE trial is used, the limited cognitive improvement would only support a price range of $11,100 to $23,100 per year.
 
The Prescribe Right Pharmaceutical Pipeline Tracker added drug reviews for drugs with PDUFA dates this spring. In our review of aducanumab, we give an in-depth analysis of the ENGAGE and EMERGE trials, the discontinuation of the trials after a futility analysis, their resurrection after a new analysis, the FDA review of the clinical data and the limitations of current Alzheimer’s therapy. We also include a review of adverse effects, votes by the FDA Peripheral and Central Nervous System Drugs Advisory Committee, an editorial in JAMA by three committee members, a look at the cost of other biologic drugs to treat neurological conditions and a summary of the ICER cost effectiveness analysis. As always, the source references for the review are included along with summaries of each article. As a subscriber, you will have access to these reviews, along with monographs for over 900 drugs to allow you to know what is coming, be ready to discuss controversial new drugs and plan for budget busting new therapies.
 
Don’t delay, subscribe today and take proactive control of your formulary. 

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.